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Acetylcysteine in paracetamol poisoning:
a perspective of 45 years of use
D. Nicholas Bateman * and James W. Dear
Paracetamol poisoning was ﬁrst reported in 1966. The development of antidotes followed within 10 years,
and by 1980 acetylcysteine (NAC) was acknowledged as the optimal therapy available. This article exam-
ines the history of the development of NAC and recent developments in its use. We oﬀer suggestions for
improvements in the way NAC may be administered and outline new developments that should have
major impacts on the way we manage paracetamol poisoning in the near future.
Introduction
Paracetamol was introduced into clinical medicine in the
1950s as an antipyretic analgesic.1,2 At that time presentations
with poisoning, either accidental or from self-harm, were
unusual in Europe. The profile of the epidemiology of poison-
ing changed over the next 40 years with poisoning becoming a
common reason for emergency admission to hospital.3 The
precise psychosocial factors behind this increase are unclear,
but by the early 1970s admissions to hospital from patients
deliberately ingesting aspirin and paracetamol had become a
regular, problematic medical emergency. The first documented
cases of organ toxicity from paracetamol were in Scotland in
1966.4,5 At that time the biochemical mechanisms underlying
paracetamol toxicity were unknown, and thus treatment was
entirely symptomatic. The major clinical presentation was of
hepatic failure due to acute liver necrosis.
The breakthrough came in the early 1970s with the develop-
ment of the concept that free radical generation during drug
metabolism was a potential cause of toxicity. Animal experiments
clearly demonstrated that the hepatic toxicity of some molecules
was by metabolism which could be both induced and inhibited,
and that it involved production of reactive intermediates in
metabolism that were normally neutralised by glutathione.6–8
The important finding was that toxicity was glutathione depen-
dant.9 This elegant chemistry explains why at standard doses
paracetamol remains one of the safest drugs used in clinical prac-
tice, but that with increasing dose hepatic toxicity becomes more
likely. The problem then, and now, is to determine the dose
threshold for toxicity in order to tailor therapy optimally.
In the early 1970s the development of an assay for paraceta-
mol, and presence of a body of patients who had ingested para-
cetamol in overdose in Edinburgh, lead to the development of
nomograms in man that illustrated the dose–response relation-
ship of paracetamol toxicity (Fig. 1).10,11 This approach thus
facilitated the development of antidotes, as it allowed compari-
son of outcomes in patients in pre-defined risk categories.
In recent years paracetamol has become an important lab-
oratory tool for investigation of drug-induced liver injury.
However, it still represents a major drug toxicity seen in over-
dose and is the most common cause of drug-induced liver
failure in many countries.12
This article is intended to give both clinicians and non-
clinical toxicologists an overview of the development of treat-
ments for paracetamol poisoning and an outline of future
therapeutic directions. We review aspects of the clinical devel-
opment of the use of NAC since the 1970s. It is based on a lit-
erature review using search terms including paracetamol, NAC
and poisoning. We have selected relevant references that illus-
trate the problems in the use of NAC, and approaches to
address these, together with the challenges in the indications
for NAC use in paracetamol overdose.
Paracetamol toxicity in medicine
Paracetamol toxicity presents in a number of scenarios. These
are principally in two types of presentation: firstly following a
single excessive ingestion, as an intentional act of self-harm, fol-
lowing accidental ingestion (usually in a child), or rarely deliber-
ately by a third party; secondly after repetitive excess ingestion,
sometimes deliberate repeated self-harm attempts, or in a thera-
peutic attempt to control a problem such as dental pain.
Paracetamol is dosed over a 24 h period by patient weight.
The dose of paracetamol that causes liver injury varies from
patient to patient, and this is a major issue for decisions on
treatment.13 Rarely, use of intravenous or oral paracetamol
may also be associated with excess dosing due to miscalcula-
tion of the dose in children, or thin and/or malnourished
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adults. While antidote therapy is appropriate in all these
cases, it is likely to be most eﬀective when given early in acute
poisoning as repeated overdose is a risk for organ toxicity.14
NAC as an antidote
The development of NAC as an antidote for paracetamol has
been described in detail elsewhere, but is relevant in relation
to current use of antidotes in paracetamol poisoning.15 The
basic understanding of toxic mechanisms of paracetamol, in
particular the potential protective role of endogenous gluta-
thione, facilitated trials in animal models of sulfhydryl donors
as potential antidotes,15,16 and demonstrated that they were
eﬀective particularly if given in the early stages of toxicity.
Three antidotes were tested in animals, cysteamine, methion-
ine and NAC.17 In the 1970s, of these agents, only NAC was
licensed in a liquid formulation for human use in the UK, and
that was as an inhalational mucolytic agent. The practical pro-
blems of drug licensing and development now encountered
were not present in the 1970s, and this facilitated the rapid
introduction and use of these untested antidotes in man.
The first antidote successfully tested in man was cyste-
amine,18 and although this was used in patients, when given
to volunteers it caused them to feel so ill that the lead investi-
gator, Laurie Prescott, was actually admitted to his own unit
overnight! Investigations then focused on the other two anti-
dotes that had been successful in animals, the orally adminis-
tered methionine and the liquid formulation of NAC, which
was administered intravenously (IV) through a microfilter in
Edinburgh, since it was not yet formulated for IV adminis-
tration.19 The microfilter was because the investigators were
concerned that, although it was sterile, the NAC might contain
micro-particulates. At that time gastric lavage was standard
therapy for overdose, and patients were often left nauseated
and vomiting after procedure. Use of an oral antidote therefore
was problematic, and this meant that although methionine
was tested, IV NAC soon became the lead agent in Europe.20–22
In the USA the FDA had required a diﬀerent approach and for
many years a 3 day oral regimen of NAC was used, before being
generally replaced by an IV regimen in the 1990s.15,23
In the 1970s patients who had ingested paracetamol
seemed to develop hepatic toxicity with monotonous regu-
larity, and there was a desire to reduce this risk by rapid
administration of the antidote. An empirical regimen was
developed which involved the use of a weight-related dose of
NAC of 300 mg per kilogram bodyweight, given in three
divided doses, 150 mg per kilogram over 15 minutes, 50 mg
per kilogram over 4 hours and 100 mg per kilogram over
16 hours.21 This regimen, often described as the Prescott
regimen, was used in the UK until 2012, when the initial infu-
sion was changed to 1 hour.24 It was also widely used else-
where in the world, although in some countries the initial
dose was given over one hour rather than 15 minutes (Table 1).
Fig. 1 Examples of nomograms for decisions on use of acetylcysteine in clinical use, showing paracetamol concentration and time after ingestion.
Left panel is the present UK nomogram (‘100 mg’ line) on a linear scale. On the right is shown the nomogram originally determined by Rumack and
Matthew (‘150 mg’ line) and the original UK (‘200 mg’ Prescott line) both on log scales. The markers on the graphs show timing and sampling of 2
examplar patients, one ( ) who developed hepatotoxicity at a concentration above UK but below other current nomograms, and one ( ) who had no
hepatotoxicity, despite having a concentration well above all current treatment lines.
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That this NAC regimen was being used by 1975, less than 10
years from the first description of paracetamol toxicity, and less
than five years from the identification of the toxic mechanism,
was an amazing achievement which no doubt saved many lives.
Progress in indication for antidote use
The only data published on the prognosis of untreated
patients who ingest diﬀerent doses of paracetamol are those of
Prescott (Table 2).25 This categorises 83 untreated patients
seen in Edinburgh in the early 1970s by the estimated dose of
paracetamol based on blood concentration at presentation as
related to a paracetamol risk nomogram. These data are illumi-
nating, as they show the individual variability in hepatic tox-
icity at apparently similar ingested doses of paracetamol.
Factors that may impact this could be variability in rates of
paracetamol metabolism to the reactive toxic intermediate, or
stores of endogenous glutathione.26 Measuring these in vivo in
man has not proved possible in real time, although there are
recent data showing that rates of production of paracetamol
sulfhydryl metabolites are greater in those who develop liver
injury, thus supporting the hypothesis that rates of paraceta-
mol metabolism are important in humans.27
Kinetic considerations
There are few studies on the pharmacokinetics of acetyl-
cysteine, and the pharmacokinetics of paracetamol are dose
dependant and altered by liver injury. The absorption of para-
cetamol after oral overdose is generally considered complete
within 4 h of ingestion. While this may not always be the case,
due to interactions of drugs that delay intestinal absorption
such as anticholinergics and opiates, for the vast majority of
cases it has proved a useful landmark for determining the
timing of paracetamol concentrations for risk assessment.28
Clearance of paracetamol is normally first order, but the rate
of clearance varies depending on the individual, but also early
onset liver injury. After therapeutic doses the half-life is
90 min to 2 h, but in liver injury it is much longer, often over
10 h.10 In contrast, the half-life of paracetamol on the nomo-
grams used for treatment decisions is 4 h (Fig. 1).
The major metabolites of paracetamol are sulphate and
glucuronide conjugates, with small amounts of the drug being
metabolised via the reactive N-acetyl-p-benzoquinone imine
(NAPQI) intermediary that is neutralised by SH groups, princi-
pally glutathione, to cysteine, mercapturic and methoxy metab-
olites.29 As the dose of paracetamol increases the simple conju-
gation pathways are saturated and more passes down the reac-
tive, potentially toxic route. This pathway can be both induced
and inhibited in animal models, and probably therefore
man, and may also be altered by pharmacogenetic
polymorphisms.30,31 However, the relevance of pharmacoge-
netics on treatment decision is unclear, and at present pheno-
typing has no practical utility in patient care. These eﬀects
may explain some of the diﬀerences in individual suscepti-
bility but testing this is challenging. Importantly to support
this hypothesis regarding human mechanisms of toxicity, the
amounts of SH-metabolites derived from NAPQI are higher in
blood in those who develop liver injury following paracetamol
overdose.32 Starvation is often used in standard animal
models of hepatotoxicity studies using paracetamol, but evi-
dence that this is important in man is unclear, though some
clinical guidelines have suggested starvation may increase the
risk of hepatotoxicity in man and that a lower threshold for
treatment with NAC should be used.24,26
There is interaction between NAC and the metabolism of
paracetamol at moderate increase in paracetamol dose, up to
3 g. Increased sulphation and glucuronidation was seen in vol-
unteers who were given NAC at these doses of higher doses of
Table 2 Number and proportion (%) of patients with untreated parace-
tamol overdose who developed liver injury (ALT >1000 IU L−1), renal
failure or death stratiﬁed by paracetamol nomogram lines. Data derived
from Prescott 1978
Paracetamol
line (mg L−1)
Number of
patients
Liver injury
N, (%)
Renal
failure N, (%)
Death
N, (%)
<100 9 0 (0) 0 0
100–200 22 5 (23) 0 0
200–300 25 6 (24) 1 (4) 0
>300 27 25 (93) 5 (20) 3 (12)
Table 1 Examples of administration regimens for IV acetylcysteine. None has been shown to either to oﬀer better or worse eﬃcacy in terms of
hepatotoxicity, but those administering the initial NAC dose over 2 or more hours are associated with fewer ADR’s (see text). All patients, whichever
regimen is used, require blood tests at the end of the infusion period to conﬁrm absence of hepatotoxicity
Total duration (prior
to check blood tests)
Initial dose
and duration
Second dose
and duration
Third dose and duration
(if part of initial regimen)
Origin and
exemplar reference
20.25 h 150 mg kg−1 over 15 min 50 mg kg−1 over 4 h 100 mg kg−1 over 16 h Prescott regimen21
48 h 140 mg kg−1 over 1 h 70 mg kg−1 over 1 h given
4 h × 12 doses
North America60
21 h 150 mg kg−1 over 1 h 50 mg kg−1 over 4 h 100 mg kg−1 over 16 h North America and
Australia62
12 h 100 mg kg−1 over 2 h 200 mg kg−1 over 10 h Subsequent doses dependent on blood
tests at 10–12 h post IV commencement
SNAP study37
20 h 200 mg kg−1 over 4 h 100 mg kg−1 over 16 h Modified Australian
study70
Toxicology Research Review
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paracetamol, indicating glutathione supply is aﬀected at even
small excesses of paracetamol.29
The mechanisms of toxicity have been recently reviewed
and are now recognised to more complex than originally
believed.33 As liver injury occurs the rate of paracetamol clear-
ance falls and the half-life lengthens, of itself a marker of
developing liver injury. The aim of NAC therapy is to neutralise
this process by providing excess glutathione. While the kine-
tics of acetylcysteine itself are understood and terminal half-
life values of between 2.7 and 5.7 h are reported,34,35 the rates
of conversion to glutathione are poorly studied in man.36 The
original dose estimates for NAC were based on extrapolation
from animal models, with the concept that rapid dosing was
clinically important.15 Models for administering NAC by novel
regimens have been used to suggest a modified 12 h infusion
would give serum concentrations of NAC adequate for
therapy.37 Comparative clinical trials have not been adequate
to determine the optimum NAC dose, but there is some evi-
dence on case series that patients ingesting very large,
‘massive’, doses of paracetamol are more likely to develop liver
injury despite prompt treatment with NAC.13,38 This has led
some to suggest higher doses of antidote should be given to
patients with this history.39
From this it is obvious that the clearance of paracetamol is
a marker of hepatic injury, but in clinical practice it has been
extremely uncommon to use this routinely in risk assessment,
other than a measurement at the end of the NAC infusion to
confirm the absence of toxicity, or suggest need for additional
antidote. The data collected on untreated patients in
Edinburgh in the early 70s still forms the basis for the nomo-
grams used internationally (Table 2).25 In the UK Prescott
advocated a treatment cut-oﬀ line of 200 mg L−1 at four hours,
with a half-life of 4 h declining from that point. In the USA,
however, the cut-oﬀ for treatment was set out a concentration
of 150 mg L−1 at four hours post ingestion, as this was 50% of
the concentration cut oﬀ for death in the untreated case
series.11,23 As illustrated in Fig. 1 some patients will be below
the cut oﬀ line and still suﬀer hepatotoxicity, and others be
well above them and not.
Uncertainty about ingested dose in many cases means that
treatment is based on rapid estimation of paracetamol concen-
tration in a blood sample taken at least 4 h after overdose.
This is now the standard of care for all patients admitted
within 12 hours of paracetamol ingestion. Since the onset of
hepatotoxicity occurs relatively quickly following paracetamol
ingestion the need to provide antidote therapy in a timely
manner results in many patients who present from 10 to
12 hours after ingestion being treated on the basis of the
history of ingested dose.
There are, however, a number of problems associated with
this rather simplistic approach to therapy. The nomograms
were based on death and occurrence of liver injury, as defined
in the 1970s as the rise in the ALT above 1000 IU L−1. This cut-
oﬀ was only chosen because it represented the enzyme activity
in blood which was the maximal measurable without sample
dilution with the assay in use at the time. Thus, although
potentially informative, it certainly does not invariably indicate
the onset of liver failure as it is based on a small Scottish
population.25
It is now appreciated that a more reliable biomarker is the
rate of increase of the ALT, which has been used either alone
or as a multiplier of paracetamol.40–42 The other important
marker traditionally used has been prothrombin time, usually
reported as INR. Changes in clotting requires exhaustion of
circulating vitamin K dependent clotting factors, which have
variable half-lives. This means it is generally 24 hours before
clotting becomes disturbed. Clinical experience has also
shown that some individual patients will develop features of
liver damage, including hepatic failure, when presenting with
an apparently verifiable history but concentrations of paraceta-
mol in blood below the nomogram interventions. This was a
problem identified with the UK treatment line (200 mg L−1 at
4 h) in the 1980s and resulted in a change in policy by the UK
poison services and a recommendation to treat patients con-
sidered at a ‘higher risk’ at an intervention line of 100 mg L−1
at 4 h.26 These problems do not appear to have been so promi-
nently reported in North America where the intervention level
was always set at 150 mg L−1 at 4 h. The Australian interven-
tion concentration has also been set at the ‘150’ line.43 A
further change in treatment intervention paracetamol concen-
tration occurred in the UK in 2012 following a single case in
which death was apparently caused by paracetamol as the
patients risk factors for toxicity were not identified at presen-
tation. The UK now operates a nomogram with treatment indi-
cated in patients above 100 mg L−1 at 4 h hours post overdose
(Fig. 1).24
The major problem for clinicians is that the standard
markers of hepatotoxicity (ALT and INR) do not usually begin
to change until sometime after ingestion at least 10 hours in
the case of ALT, and 24 hours for INR. A further complication
is that NAC and paracetamol both aﬀect INR, resulting in a
moderate increase in some patients usually in the range of 1.2
to 1.7.44–46
The eﬀect of these problems has been that patients are
treated because they may be at risk rather than that they are at
risk. It is diﬃcult to estimate how many patients are treated
who would not get liver damage if left untreated. So few
patients were in the original untreated cohort that confidence
intervals to estimate this accurately are not really possible,
although the data shown in Table 2 suggests that many
patients would presumably not develop major clinical pro-
blems, even with paracetamol concentrations in the range in
which some patients do. It is worth bearing in mind that tens
of thousands of patients are admitted every year to UK hospi-
tals for NAC treatment, and likely hundreds of thousands
worldwide.47
This problem has led to the consideration of other
approaches to risk assessment in early presentations with
paracetamol overdose. Over the past few years it has become
evident that when injured, liver cells release a range of mole-
cules into the circulation. A full-length version of the protein
keratin-18 (K18) is released by necrotic cell death. A shorter,
Review Toxicology Research
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caspase cleaved form of K18 (ccK18) is released following cell
apoptosis (programmed cell death). Both forms of K18, when
measured in the first serum sample at presentation at the hos-
pital after paracetamol overdose, correlate with peak ALT
activity during the hospital stay.48,49 K18 is more sensitive
than ALT – it distinguishes patients with and without acute
liver injury at hospital presentation when ALT activity is still in
the normal range. K18 is supported for exploratory use in
assessing drug-induced liver injury in clinical trials, both by
the EMA and the FDA.50,51 MicroRNA-122 (miR-122) is a
microRNA biomarker specific for liver injury that is fully con-
served (translational) across in vitro models, in vivo models
and humans. Similar to K18, miR-122 is an early marker for
acute liver injury that predicts a rise in ALT activity following
paracetamol overdose. When miR-122 was measured at hospi-
tal presentation after a paracetamol overdose in patients
requiring subsequent NAC therapy the circulating miR-122
concentration correlated significantly with peak hospital stay
ALT activity and was significantly higher in those patients who
developed subsequent acute liver injury.48,49 This is consistent
with miR-122 having enhanced sensitivity and specificity in
this context-of-use.
The uncertainty at this point is when it would be safe to dis-
charge patients without rises in the novel markers. At present,
all patients in these cohorts studied have received NAC and the
abnormalities in ALT and other biomarkers seen are all in
patients who received the antidote. Developing studies that
allow us to understand whether an initial normal biomarker
indicator at a given time interval will safely allow discharge
without therapy or will permit administration of perhaps a
single dose of antidote prior to discharge is one of the next big
challenges.
Such information is necessary because of the other pro-
blems associated with NAC, in particular its propensity to
cause adverse eﬀects and need for hospital admission.
Adverse eﬀects of NAC
As intravenous NAC became more widely used problems
associated with its administration became clearer. The mar-
keted formulation of the drug required calculation of the
numbers of ampoules required to provide the correct dose,
and in the early days of its use by staﬀ unfamiliar with the
mode of administration dosing errors occurred, resulting in
rare deaths. Flushing had been recognised by the early investi-
gators in Edinburgh in some patients who had received NAC,
but as it came to be used more widely more serious adverse
eﬀects were reported, in particular anaphylactoid reactions,
including in severe cases major bronchospasm and hypoten-
sion. Interestingly, the first case reported was in a patient who
had low concentrations paracetamol at the time of treatment,
and almost certainly therefore did not require therapy.52 This
low concentration of paracetamol was not recognised at the
time as a likely key factor in the adverse event. It was not until
the early years of the 20th century that retrospective studies,
using prescription of antihistamines and bronchodilators after
use of NAC as a surrogate for anaphylaxis, showed a clear
relationship between the concentration of paracetamol and
risk of reaction. Rarely NAC has caused serious reactions and
death, but these seem likely related to inadvertent excess
dosing.53,54
Earlier studies had suggested individual susceptibility to
the reactions based on skin testing using the antidote solution
intradermally.55 As physicians became familiar with this
problem standard approaches were developed to treatment.
Importantly this reaction does not involve an immunological
mechanism but is almost certainly related to histamine release
from basophils exposed to high concentrations of NAC. Cohort
studies comparing concentrations of paracetamol in patients
receiving NAC showed a clear concentration eﬀect relationship
of paracetamol as protective of the anaphylactoid
response.46,56,57 From a practical clinical perspective this
means that patients who are treated with NAC at lower concen-
trations of paracetamol, either because of the lower ingestion,
or a later presentation to hospital, are at increased risk of
adverse eﬀects. Unfortunately, even though the adverse reac-
tion is not immunological, previous history of such reactions
sometimes deterred both patients and doctors from use of the
antidote. Furthermore, in the patients who developed adverse
reactions the antidote regimen had to be discontinued to alle-
viate the symptoms, thus potentially delaying therapy and
prolonging hospital stay.
The frequency of detection of adverse reactions is well
known to be dependent upon the methods chosen to ascertain
them. The case of NAC illustrates this very well. Many clini-
cians will say they have never seen an adverse reaction, but of
course most doctors will not be present at the time this occurs
since adverse eﬀects normally begin about an hour after the
infusion of the antidote has commenced, when the physician
has left to see other patients.
The incidence of reactions will be best tested under con-
ditions of a formal clinical trial, and only one placebo-con-
trolled trial has been conducted in which therapies were used
to mitigate the risk of anaphylactoid responses.37 This was a
study conducted using an antiemetic as the prophylactic, since
vomiting is also a recognised adverse eﬀect of intravenous
NAC. In this study anaphylactoid responses requiring interven-
tion or therapy were detected in 30% of the cases receiving the
standard NAC regimen.47 This is much higher than has been
previously documented, where the techniques used to detect
reactions have tended to involve monitoring of specific thera-
pies such as antihistamines and bronchodilators using pre-
scription records. Using this methodology ADR rates generally
range between about 5 and 10%.58
The precise mechanisms underlying the adverse reaction
have been examined in a study in patients receiving NAC for
paracetamol overdose. This indicated that peak concentrations
of NAC were related to the onset of the adverse eﬀect, but inter-
estingly there was no obvious diﬀerence in that concentration
in patients who developed or did not develop an anaphylactoid
response. The key diﬀerence was in the concentration of circu-
Toxicology Research Review
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lating histamine, which was much higher in those with the
reactions.46 The origins of this histamine release seem most
likely to be basophils, since the normally accepted marker of
mast cell degranulation, tryptase, was unchanged. These find-
ings therefore suggest, as previously demonstrated in volun-
teers using intradermal injections,55 that some patients are
indeed predisposed to have an anaphylactoid response.
Remarkably though the concentration of paracetamol in blood
also aﬀects the frequency of these reactions, although the
mechanism of this eﬀect has not been determined. This is
been shown in a number of studies in which patients who
received NAC were grouped by paracetamol concentration at
time of admission. The incidence of reactions is inversely
related to paracetamol concentration above be 100 mg L−1
treatment line.59 The net eﬀect of these findings is that redu-
cing the intervention concentration for paracetamol, in an
attempt to completely prevent risk of hepatic toxicity, will
inevitably increase the incidence of adverse eﬀects to the
antidote.
Implications for dosing of NAC:
newer regimens
The dose of NAC used in the initial studies intravenously was
empirical and based on theoretical calculations. In North
America the oral regimen adopted, principally because of the
lack of licensed liquid preparation in the USA at that time,
involved 140 mg kg−1 as a first loading dose followed by main-
tenance dose of 70 mg kg−1 4 hours after the loading dose,
repeated every 4 hours for a total of 17 maintenance doses.23
This regimen, therefore, took approximately three days to
administer, whereas in the UK the majority of patients had
been discharged within 24 hours. This mismatch has been
resolved over the years as US physicians using an oral regimen
have examined the eﬃcacy of shorter durations of oral therapy,
but more importantly with the adoption of the intravenous
approach across the USA, albeit initially over 48 h.60
There has been debate about which is the most eﬀective
route for NAC, since the oral one should deliver more eﬃcien-
tly to the liver during first pass, but no direct comparative
trials.61 Retrospective comparison of 2 cohorts of patients
treated in North America, intravenous in Canada and orally in
the USA, showed very little diﬀerence in eﬃcacy measured as
incidence of liver injury. Death rates were too low to allow any
demonstration of the eﬀect on mortality. Thus there seemed
little evidence of diﬀerence in benefit to the majority of
patients of giving the potentially larger doses provided orally.62
One key diﬀerence has been the far fewer anaphylactoid
ADRs reported in the literature with oral NAC. There has also
been some uncertainty as to the need to give such large initial
doses of NAC IV as the oral regimen seems as eﬀective.15 The
clinical trial conducted in the UK of a simpler 12 h infusion
regimen, using 200 mg per kg body weight over 4 h followed
by 100 mg kg−1 over 8 h was not powered to demonstrate equi-
valent eﬃcacy, though there was no signal of a greater risk of
hepatic injury using the shorter, simpler regimen using con-
ventional or novel biomarkers.47 Since this study others have
confirmed that a slower initial infusion results in fewer ADRs.
The 12 h NAC regimen is now routine clinical practice in a
number of UK hospitals.63 In an audit of over 3300 patients
there was no diﬀerence in liver injury or liver synthetic dys-
function between regimens (unpublished). This multi-centre
study confirmed that the 12 h regimen was associated with
fewer anaphylactoid reactions as measured by rate of anti-
histamine prescription (11% with the 21 h regimen, 2% with
the 12 h regimen). We believe that the 12 h regimen should be
the standard of care given its enhanced safety profile, equi-
valent eﬃcacy and shorter duration. Furthermore, patients
with liver injury receive NAC at a quicker rate (compared to the
21 h regimen). For example, in the first 21 h, patients with the
new regimen receive 500 mg kg−1 NAC if they have injury (such
as an increase in ALT) compared with 300 mg kg−1 of NAC with
the standard regimen (Table 1). An alternative approach to a
shorter IV treatment time has been studied in a study in which
a lower (250 mg kg−1 NAC over 12 h) was compared to a stan-
dard 20 h 300 mg regimen, with the decision to stop therapy
being made on blood tests at 12 h.64 Whist this study confirms
that blood testing at 12 h into an infusion is useful, the logic of
the reduced initial dose of NAC in the 12 h group seems ques-
tionable to us, and this seems to oﬀer no advance on SNAP.
Future developments
Predicting the future is always a challenge, however, there are
some indicators that recent developments may allow the devel-
opment of a new approach to managing paracetamol overdose,
including a better targeting of the use of NAC.
The first change possible should be the better identification
of patients at risk of paracetamol induced liver injury. Based
on the studies done to date looking at new microRNA and
protein biomarkers it is clear that changes in these markers
occur earlier than the traditional measures currently used.
This indicates that liver injury has started before NAC is admi-
nistered in virtually all patients who develop a subsequent ALT
increase. Importantly the newer biomarkers provide better
diﬀerentiation than that provided by the current treatment
nomograms. One caveat is that all patients in whom bio-
markers have been evaluated to date have received NAC.
Further work will have to be done, firstly to provide biomarker
analysis that is reliable and quick, and current developments
suggest it was will be possible, and secondly to ensure that a
normal biomarker concentration at a given time point after
overdose is a reliable indicator of good outcome without NAC
treatment.65 It is clear, however, that new biomarkers can accu-
rately identify those patients who will get liver injury despite
NAC treatment, which provides a new mechanism for identify-
ing those patients who should be treated with diﬀerent thera-
peutic approaches (see below).
Secondly, from our experience we would urge all clinicians
now treating paracetamol poisoning with slower initial NAC
Review Toxicology Research
Toxicol. Res. This journal is © The Royal Society of Chemistry 2019
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
9 
A
pr
il 
20
19
. D
ow
nl
oa
de
d 
on
 5
/9
/2
01
9 
2:
32
:1
1 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
infusions to also consider a shorter overall course in line with
that we have published.47 This has 3 advantages, simplicity in
use, fewer ADRs and shorter time on an infusion for most
patients. As described above, it also allows additional NAC to be
administered earlier in those who are identified at risk of devel-
oping hepatotoxicity at an earlier time of 12 h into therapy.
Any pharmacologist or toxicologist who looks at NAC
dosing regimens will be surprised that the same dose of anti-
dote is used initially in all patients irrespective of the dose of
paracetamol. Since NAC is theoretically given to replace
endogenous glutathione consumed by the production of the
reactive paracetamol metabolite the logic of giving the same
dose of antidote to everyone seems clearly flawed. Indeed,
studies in the 1980s show that in patients who developed liver
failure benefited from continuing doses of NAC after the end
of the 21 hours initial infusion.66 This has led to the use of
extended NAC infusion in patients to have any evidence of sig-
nificant liver damage, now usually assessed by changes in the
concentrations of ALT or in the INR.
Establishing whether higher doses of antidote are necessary
in patients taking large overdoses is a clinical challenge. There
is evidence that patients taking doses of paracetamol causing
concentrations in blood above a concentration nomogram
commencing at 300 mg L−1 four hours post overdose have
larger rises in hepatic enzymes and a greater frequency of sig-
nificant liver injury when compared to cohorts treated in the
same hospitals with lower concentrations of paracetamol.38,67
Some clinicians already advise using higher doses of NAC in
such patients, but clinical trial evidence supporting this
approach is lacking. Because the new 12 h regimen is not dose
limited by toxicity (such as anaphylactoid reactions), there is
the potential to give higher doses to patients with high para-
cetamol body loads without inducing unacceptable side eﬀects.
The final challenge is to consider what other treatments
might be possible in patients who are either at a significant
risk of, or are developing, liver injury with its potentially fatal
outcome. Studies have shown that a number of agents oﬀer
potential for alleviating or preventing liver injury in animal
models.68 The diﬃculty has always been that these drugs are
potentially toxic and expensive. Determining which patients to
enter into a clinical trial early enough for them to be eﬀective in
man is also problematic. A new approach may now be possible,
however, because of the availability of biomarkers that are diﬀer-
entiating early in the course of liver injury. Newer, potentially
safer, hepato-protective agents are in development, and one
agent, calmangafodipir,69 has completed phase 1 studies in
patients (clinicaltrials.gov: NCT03177395). Is to be hoped within
the next 10 years that such agents, in combination with NAC,
will eventually fully mitigate the eﬀects of paracetamol overdose.
Conclusion
We are now in a position to significantly refine the treatment
of paracetamol overdose. To date we have used a sub-optimal
‘one size fits all’ dosing regimen that was not based on robust
dose finding studies. In the near future a precision medicine
approach will be used in clinical practice with patients identi-
fied as higher or lower risk at first presentation to hospital.
This will allow robust clinical trials testing the clinical and
cost eﬀectiveness of new treatment pathways. It is the authors’
opinion that a 12 h NAC regimen should be the standard of
care because it is safer in use, is as eﬀective, and shorter in
duration compared with historic protocols.
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